Abstract
A prospective randomized trial in patients with previously untreated multiple myeloma was performed comparing carmustine (BCNU), cyclophosphamide, and prednisone (BCP) to melphalan (Alkeran) and prednisone (AP). Induction response rates, remission duration, and survival were similar with both regimens. Hematologic toxicity was greater with AP. Crossover studies in patients who relapsed did not illustrate any significant activity with either drug treatment program. Therefore, BCP can be utilized as initial therapy in myeloma because of comparable remission rates and less hematologic toxicity.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aged
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols*
-
Carmustine / administration & dosage
-
Carmustine / adverse effects
-
Clinical Trials as Topic
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Drug Therapy, Combination
-
Female
-
Humans
-
Male
-
Melphalan / administration & dosage
-
Melphalan / adverse effects
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Prednisone / administration & dosage
-
Prednisone / adverse effects
-
Prognosis
-
Prospective Studies
-
Random Allocation
Substances
-
Antineoplastic Agents
-
Cyclophosphamide
-
Melphalan
-
Carmustine
-
Prednisone
Supplementary concepts
-
AP protocol 2
-
BCP protocol